Cancer Genetics and Kreatech form cancer deal
This article was originally published in Clinica
Executive Summary
Cancer Genetics and Dutch firm Kreatech Biotechnology have signed a deal to commercialise novel DNA probe assays for diagnosing and monitoring cancer. Under the conditions of the licence & product supply agreement, CGI's novel DNA preparation and probes for detecting and monitoring haematopoietic malignancies is being combined with Kreatech's Universal Linkage System (ULS) labelling technology to produce ULS-labelled DNA probes for fluorescent in situ hybridisation analyses. Cambridge, Massachusetts-based CGI plans to start selling the probes in Europe in the fourth quarter of 2002 and in the Asian and US markets in early 2003.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.